Highlight
– JAK inhibitors are associated with a significantly increased risk of pulmonary embolism (PE) and deep vein thrombosis (DVT) compared to dupilumab and methotrexate in patients with atopic dermatitis (AD).
– No significant differences in thromboembolic risk were observed between JAK inhibitors and cyclosporine.
– The study supports a personalized approach to JAK inhibitor use, especially in patients with pre-existing thromboembolic risk factors.
